| Company/Division name | Regeneron Pharmaceuticals |
| Parent company | Regeneron |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 1000 |
| Year reshoring announced: | 2025 |
| Capital investment ($): | 2000 |
| City reshored to: | Saratoga Springs |
| State(s) reshored to: | NY |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption, Tariffs |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Image/brand, Impact on domestic economy, Infrastructure, Skilled workforce availability/training, Under-utilized capacity |
